0.03Open0.03Pre Close0 Volume2.04K Open Interest2.00Strike Price0.00Turnover369.62%IV93.33%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier6DDays to Expiry0.03Extrinsic Value100Contract SizeAmericanOptions Type0.1404Delta0.4362Gamma35.00Leverage Ratio-0.0087Theta0.0000Rho4.91Eff Leverage0.0003Vega
Immunic Stock Discussion
Immunic Highlights 2024 Accomplishments and Upcoming Milestones
Tuesday, 7th January at 6:30 am
– Top-Line Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis Expected in April –
– Reported Positive Outcome from Interim Analysis of Ongoing, Twin Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis; Both Trials on Track to Be Completed in 2026 –
– Strengthened Management Team and Board of Directors with Key Hir...
Anything Important?
No comment yet